Brainstorm Cell Therapeutics

OverviewSuggest Edit

Brainstorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson’s Disease. The Company's platform technology, NurOwn®, uses proprietary culture conditions to induce mesenchymal stem cells to secrete high levels of neurotrophic factors known to promote the survival of neurons. NurOwn® cells dampen the immune system and secrete growth factors that help damaged neurons survive.

TypePublic
Founded2004
HQNew York, US
Websitebrainstorm-cell.com

Latest Updates

Employees (est.) (Dec 2018)31(+30%)
Share Price (Jun 2019)$3.6

Key People/Management at Brainstorm Cell Therapeutics

Chaim Lebovits

Chaim Lebovits

President and Chief Executive Officer
Ralph Kern

Ralph Kern

Chief Operating Officer and Chief Medical Officer
Arturo Araya

Arturo Araya

Chief Commercial Officer
Joseph Petroziello

Joseph Petroziello

VP of Scientific and Corporate Communications
Susan E. Ward

Susan E. Ward

Head of Clinical Operations
Eyal Rubin

Eyal Rubin

EVP, Chief Financial Officer
Show more

Brainstorm Cell Therapeutics Office Locations

Brainstorm Cell Therapeutics has offices in New York and Petah Tikva
New York, US (HQ)
1325 6th Ave 28th Floor
Petah Tikva, IL
Basel St 12, Petah Tikva
Show all (2)

Brainstorm Cell Therapeutics Financials and Metrics

Brainstorm Cell Therapeutics Revenue

USD

Net income (Q2, 2019)

(4.9m)

EBIT (Q2, 2019)

(4.9m)

Market capitalization (10-Jun-2019)

106.8m

Closing stock price (10-Jun-2019)

3.6

Cash (30-Jun-2019)

1.1m
Brainstorm Cell Therapeutics's current market capitalization is $106.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

2.1m2.6m3.6m2.8m4.0m5.8m

R&D expense

2.9m4.8m4.9m

Operating expense total

5.0m7.4m8.5m2.8m4.0m5.8m

EBIT

(4.9m)(7.4m)(8.5m)(5.1m)(5.0m)(14.1m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

General and administrative expense

272.0k351.0k417.0k856.0k960.0k988.0k1.1m826.0k848.0k829.0k1.2m1.3m1.6m1.3m1.5m1.3m

Operating expense total

1.1m1.0m1.3m2.4m960.0k988.0k1.1m826.0k848.0k829.0k1.2m1.3m2.9m1.3m1.5m1.3m

EBIT

1.1m2.1m2.0m2.4m2.2m(2.4m)(2.6m)(1.8m)(1.6m)(1.8m)(2.4m)(2.3m)(3.1m)(3.2m)(4.9m)(4.9m)

Net Income

1.1m2.1m2.0m2.4m(2.2m)(2.3m)(2.6m)(1.8m)(1.6m)(1.8m)(2.4m)(2.3m)(3.1m)(3.2m)(5.0m)(4.9m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

3.5m4.3m428.0k547.0k2.5m942.0k

Accounts Receivable

24.5m2.0m

Inventories

74.0k

Current Assets

4.4m9.6m16.8m10.4m9.6m10.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

329.0k3.0m11.3m9.0m3.5m1.3m710.0k2.2m955.0k604.0k2.5m3.2m2.3m697.0k3.2m1.1m

Current Assets

5.7m3.9m12.2m11.1m22.1m20.1m18.1m13.5m11.4m8.7m11.0m7.9m19.6m12.6m8.3m5.5m

PP&E

267.0k327.0k302.0k272.0k290.0k282.0k268.0k281.0k312.0k281.0k358.0k412.0k596.0k564.0k611.0k599.0k

Total Assets

6.2m4.2m12.5m11.4m22.4m20.4m18.4m13.8m11.7m9.0m11.3m9.4m21.0m13.8m11.9m8.9m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(4.9m)(9.2m)(8.5m)(5.0m)(5.0m)(13.9m)

Depreciation and Amortization

77.0k85.0k110.0k

Inventories

Accounts Payable

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(1.1m)(2.1m)(2.0m)(6.5m)(2.2m)(2.3m)(7.1m)(1.8m)(1.6m)(1.8m)(2.4m)(2.3m)(3.1m)(3.2m)(5.0m)(9.9m)

Depreciation and Amortization

17.0k16.0k23.0k25.0k31.0k33.0k44.0k77.0k

Purchases of PP&E

(31.0k)(94.0k)(94.0k)(16.0k)(28.0k)(26.0k)(11.0k)(86.0k)(45.0k)(215.0k)(1.0k)(4.0k)(25.0k)
USDY, 2019

Financial Leverage

-2 x
Show all financial metrics

Brainstorm Cell Therapeutics Online and Social Media Presence

Embed Graph

Brainstorm Cell Therapeutics News and Updates

BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress

NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will present scientific data at the 35th Congress of the European Committee for…

BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida

NEW YORK, Jan. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits, CEO will provide a corporate overview presentation …

Brainstorm Cell Therapeutics Frequently Asked Questions

  • When was Brainstorm Cell Therapeutics founded?

    Brainstorm Cell Therapeutics was founded in 2004.

  • Who are Brainstorm Cell Therapeutics key executives?

    Brainstorm Cell Therapeutics's key executives are Chaim Lebovits, Ralph Kern and Arturo Araya.

  • How many employees does Brainstorm Cell Therapeutics have?

    Brainstorm Cell Therapeutics has 31 employees.

  • Who are Brainstorm Cell Therapeutics competitors?

    Competitors of Brainstorm Cell Therapeutics include InVivo Therapeutics, LifebankUSA and AFYX Therapeutics.

  • Where is Brainstorm Cell Therapeutics headquarters?

    Brainstorm Cell Therapeutics headquarters is located at 1325 6th Ave 28th Floor, New York.

  • Where are Brainstorm Cell Therapeutics offices?

    Brainstorm Cell Therapeutics has offices in New York and Petah Tikva.

  • How many offices does Brainstorm Cell Therapeutics have?

    Brainstorm Cell Therapeutics has 2 offices.